DexCare raises $50 million and other funding for digital health

DexCare scored $50 million in a Series B funding round led by Transformation Capital. Existing investors Kaiser Permanente, Providence Ventures, Mass General Brigham, Define Ventures, Frist Cressey Ventures and SpringRock Ventures also participated.

Series B arrives less than a year after a Fundraising of $20 million starting in March.

The Providence Health spin-out provides a platform for health systems to find new patients, navigate their care, and manage staff and resources to meet demand.

“Hospitals are moving to hybrid care and need a single solution to attract new patients and connect them virtually and in person with their own caregivers,” co-founder and CEO Derek Streat said in a statement.

“This investment will help us accelerate platform development and go-to-market progress for our growing number of leading healthcare systems such as Kaiser Permanente, Providence, Mass General Brigham, CHS, Houston Methodist and others. Transformation Capital’s focus on digital health will help us achieve these goals, along with our current lineup of leading healthcare-focused partners.


DeepScribe, an AI-powered clinical documentation tool for healthcare providers, raised $30 million in funding.

The round was led by Nina Achadjian at Index Ventures, with participation from Scale.ai CEO, Figma CEO Dylan Field, and existing investors Bee Partners, Stage 2 Capital and 1984 Ventures.

The company closed a $5.2 million seed round in May. According to Cruchbase, DeepScribe’s total raise is now $37.2 million.

“We believe ambient voice technology is the key to transcending AI in medicine, from simply improving workflow efficiency to actually improving healthcare outcomes,” the co-founders said. Akilesh Bapu and Matthew Ko in a statement.

“Doctor-patient conversations contain the richest information, but busy, exhausted clinicians don’t have the bandwidth to document all that data and do anything meaningful with it. DeepScribe aims to change that.


AI-based cancer risk stratification platform PreciseDx has raised $10.75 million in a Series A funding round led by the Merck Global Health Innovation Fund.

Other participating investors include Mount Sinai Health System, Agilent Technologies, IBM Ventures and The Hobart Group.

The company plans to use the money to develop and commercialize other cancer diagnostics and to support clinical trials.

“Merck GHI is delighted to support PreciseDx as they help accelerate the digitization of pathology,” said David M. Rubin, PhD, Chief Executive Officer of Merck GHI, in a statement. “Personalised, AI-powered healthcare is the future. We believe the ability to create and leverage billions of new data points has the potential to truly change cancer treatment.”


Starting care coordination HeyRenee secured $4.4 million in Seed II funding.

The round was led by Quiet Capital, with participation from City Light Capital, Fika Ventures, Global Founders Capital, Mucker Capital, SaaS Ventures and Tau Ventures. The company said its total raise now stands at $8.2 million and plans to launch its service in early spring this year.

“HeyRenee is a personal healthcare assistant that unifies the myriad of complex aspects of healthcare into one intuitive and delightful experience specifically designed for disadvantaged older Americans who often have low knowledge of health and technology and multiple health, social and cultural factors that require coordinated attention to achieve better results,” co-founder and CEO Nick Desai said in a statement.

“Quiet Capital and Morgan Livermore are exceptionally high value-added lead investors. Along with Fika, Tau, and our other investors, they fuel our relentless pursuit of health equity for all Americans.

Comments are closed.